Bristol-Myers Squibb Company (NYSE: BMY) is one of the stocks Jim Cramer recently shed light on. When a caller noted that the ...

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

The objective response rate (ORR) was 32% with adagrasib versus 9% with docetaxel (OR 4.68, 95% CI 2.56-8.56, P <0.0001), ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Last week, President Trump sent letters to 17 major pharmaceutical companies advising them to work with his administration to ...

Quarterly revenue from Yescarta came in at $393 million, which was a 5% decline from the second quarter of last year, while ...

Flaws remain for office in the San Francisco Peninsula office — but demand is starting to improve, as net absorption was -406 ...

Key Points On July 22, 2025, the U.S. Food and Drug Administration issued a Complete Response Letter for RP1, delaying potential commercialization and revenue. Research and development expenses ...

Patients with inflammatory bowel disease (IBD) have a 48% greater relative risk of developing interstitial lung disease (ILD) ...

Covenant Health has announced the launch of CAR T-cell therapy at the Joe Arrington Cancer Research & Treatment Center (JACC) ...

Some high-profile healthcare names are at even cheaper valuations. For example, Merck is trading at a forward P/E of 8.7, ...